FDA 483 - GlaxoSmithKline Vaccines Srl - January 26, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
GlaxoSmithKline Vaccines Srl in Sovicille, Rosia, Italy, was cited for significant deficiencies across its quality system during an FDA inspection. Observations included failures in thoroughly investigating discrepancies and batch failures, inadequate quality control unit procedures for deviation management and CAPA effectiveness, lapsed employee training for critical functions, and late reporting of numerous adverse drug experiences to the FDA. Additionally, laboratory control mechanisms were not consistently followed, impacting data integrity.
ID · d8536c3e-0969-4205-b7bc-ad1efe78cfdb